Skip to main content
OpenTrials
Completed

NCT Number: NCT02225821

Wound Infections Following Implant Removal

In the Netherlands about 18,000 surgical procedures with implant removal are annually performed after fracture healing, of which 30-80% concern the foot, ankle and lower leg region. For clean surgical procedures, the rate of postoperative wound infections (POWIs) should be less than 5%. However, rates of 10-12% following implant removal, specifically after foot, ankle and lower leg fractures are reported. Currently, surgeons decide individually if antibiotics prophylaxis is given, since no guideline exists. This leads to undesirable practice variation.

Therefore, the investigators propose a double-blind randomized controlled trial (RCT) in patients scheduled for implant removal following a foot, ankle or lower leg fracture, to assess the (cost-)effectiveness of a single gift of antibiotic prophylaxis. Primary outcome is a POWI within 30 days after implant removal. Secondary outcomes are quality of life, functional outcome at 30 days and 6 months after implant removal and costs.

With 2 x 250 patients a decrease in POWI from 10% to 3.3% (expected rate in clean-contaminated elective orthopedic trauma procedures) can be detected (Power=80%, 2-sided alpha=5%, including 15% lost to follow up).

If the assumption of the investigators, that prophylactic antibiotics prior to implant removal reduces the infectious complication rate, is confirmed by this RCT, this will offer a strong argument to adopt a single gift of antibiotic prophylaxis as standard practice of care. This will reduce the incidence of POWIs and consequently will lead to less physical and social disabilities and health care use. In addition, it will decrease the rate of use of empiric broad-spectrum antibiotics (and antibiotic resistance) prescribed upon suspicion or diagnosis of a POWI. A preliminary, conservative estimation suggests yearly cost savings in the Netherlands of €3.5 million per year.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Medisch Centrum Alkmaar, Alkmaar, Netherlands

Loading trial locations.

About this study

See study protocol

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients ≥18 years and ≤75 years of all ethnic backgrounds
  • Implant removal following foot, ankle and/or lower leg surgery

Exclusion criteria

  • Removing and re-implanting osteosynthesis material in the same session
  • Active wound infection or (plate) fistula
  • Antibiotic treatment at time of elective implant removal for a concomitant disease or infection
  • A medical history of an allergic reaction to a cephalosporin, penicillin, or any other β-lactam antibiotic.
  • Insufficient comprehension of the Dutch language to understand the patient information to make an informed decision to participate.
  • Kidney disease (eGFR <60 ml/min/1.73m^2).
  • Treatment with probenecide, anticoagulants (see SPC)
  • Pregnancy and lactation

Treatment and study plan

Cephalozin

Drug

1000 mg Cephalozin

Other names: Kefzol

Sodium Chloride

Other

10 cc of NaCl 0.9%

Other names: NaCl 0.9%

Primary outcomes

  1. Postoperative wound infection (POWI)

    Time frame: 30 days

    The primary outcome variable is a POWI within 30 days after implant removal as defined by the criteria applied by the Centers for Disease and Control.

Secondary outcomes

  1. Health-related quality of life

    Time frame: baseline, one month, 6 months

    Health-related quality of life (as measured by the EQ-5D questionnaire)

  2. Functional outcome

    Time frame: baseline, 1 month, 6 months

    Functional outcome following implant removal as assessed with the Lower Extremity Functional Scale (LEFS). The LEFS can be used by clinicians as a measure of patients' initial function, ongoing progress and outcome, as well as to set functional goals. The LEFS can be used to evaluate the functional impairment of a patient with a disorder of one or both lower extremities. It can be used to monitor the patient over time and to evaluate the effectiveness of an intervention

  3. Patient satisfaction

    Time frame: 1 month, 6 months

    Patient satisfaction following implant removal as measured by a ten-point Visual Analog Scale

  4. Health care resources utilization

    Time frame: baseline, 1 month, 6 months

    Health care resources utilization at baseline, 1 month and 6 months after implant removal (including amongst others, number of visits to the general practitioner and use of home care organizations) as measured by way of a combination of the Dutch iMTA Medical Consumption Questionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ) (adapted to the study setting).

Other outcomes

  1. Costs

    Time frame: Costs per quality adjusted life year

    Costs (economic evaluation including budget impact analysis): the economic evaluation of antibiotic prophylaxis in patients scheduled for implant removal (following a foot, ankle or lower leg fracture) against no prophylaxis as its best alternative will be performed as a cost-effectiveness (CEA) as well as a cost-utility (CUA) analysis.

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Collaborators

  • AO Research Fund
  • ZonMw: The Netherlands Organisation for Health Research and Development

Registry information

Official study title

Antibiotic Prophylaxis to Prevent Wound Infections Following Implant Removal

Acronym: WIFI

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Aug 26, 2014
Registry last updated
Dec 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.